MCRB Seres Therapeutics, Inc.

Nasdaq serestherapeutics.com


$ 16.75 $ 0.32 (1.95 %)    

Friday, 14-Nov-2025 15:44:20 EST
QQQ $ 608.92 $ 9.36 (1.56 %)
DIA $ 471.89 $ 0.52 (0.11 %)
SPY $ 672.11 $ 6.66 (1 %)
TLT $ 88.91 $ -0.88 (-0.98 %)
GLD $ 375.98 $ 3.09 (0.83 %)
$ 16.765
$ 16.80
$ 16.69 x 100
$ 16.88 x 1
$ 16.46 - $ 17.60
$ 6.53 - $ 24.67
95,692
na
151.66M
$ 1.11
$ 28.12
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-05-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-07-2025 03-31-2025 10-Q
4 03-13-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 03-05-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-07-2023 12-31-2022 10-K
13 11-02-2022 09-30-2022 10-Q
14 08-03-2022 06-30-2022 10-Q
15 05-04-2022 03-31-2022 10-Q
16 03-01-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-03-2021 06-30-2021 10-Q
19 05-04-2021 03-31-2021 10-Q
20 03-02-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 07-28-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 03-02-2020 12-31-2019 10-K
25 11-05-2019 09-30-2019 10-Q
26 08-06-2019 06-30-2019 10-Q
27 05-02-2019 03-31-2019 10-Q
28 03-06-2019 12-31-2018 10-K
29 11-08-2018 09-30-2018 10-Q
30 08-02-2018 06-30-2018 10-Q
31 05-09-2018 03-31-2018 10-Q
32 03-08-2018 12-31-2017 10-K
33 11-08-2017 09-30-2017 10-Q
34 08-03-2017 06-30-2017 10-Q
35 05-04-2017 03-31-2017 10-Q
36 03-16-2017 12-31-2016 10-K
37 11-10-2016 09-30-2016 10-Q
38 08-11-2016 06-30-2016 10-Q
39 05-16-2016 03-31-2016 10-Q
40 03-14-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 seres-therapeutics-q3-eps-094-beats-067-estimate-sales-351000k-miss-5875m-estimate

Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0...

 seres-therapeutics-announces-actions-to-reduce-operating-costs-reducing-workforce-by-about-25-workforce-reduction-to-result-in-cash-charges-of-1m-14m

On September 23, 2025, Seres Therapeutics, Inc. (the "Company") announced actions to reduce operating costs in order to...

 seres-therapeutics-receives-fda-feedback-to-finalize-phase-2-protocol-for-ser-155-in-preventing-bsis-in-allo-hsct-patients

Following recent constructive FDA feedback, Seres anticipates finalizing SER-155 Phase 2 study protocol for the prevention of b...

 seres-therapeutics-q2-eps-227-beats-265-estimate

Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(2.27) per share which beat the analyst consensus estimate of $(...

 chardan-capital-downgrades-seres-therapeutics-to-neutral-raises-price-target-to-6

Chardan Capital analyst Keay Nakae downgrades Seres Therapeutics (NASDAQ:MCRB) from Buy to Neutral and raises the price targ...

 seres-therapeutics-q1-eps-375-beats-012-estimate

Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $3.75 per share which beat the analyst consensus estimate of $0...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION